Related content

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

By He Kan  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 36, Iss. 3, 2011-09 ,pp. : 129-139

Springer Publishing Company

Access to resources Recommend Favorite

Zoniporide: a potent and highly selective inhibitor of human Na + /H + exchanger-1

By Marala R.B.   Brown J.A.   Kong J.X.   Tracey W.R.   Knight D.R.   Wester R.T.   Sun D.   Kennedy S.P.   Hamanaka E.S.   Ruggeri R.B.   Hill R.J.  

European Journal of Pharmacology, Vol. 451, Iss. 1, 2002-09 ,pp. : 37-41

Elsevier

Access to resources Recommend Favorite

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 312-318

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Flavone Propargyl Ethers as Potent and Selective Inhibitors of Cytochrome P450 Enzymes 1A1 and 1A2

By  

Drug Metabolism Letters, Vol. 6, Iss. 4, 2012-12 ,pp. : 275-284

Bentham Science Publishers

Access to resources Recommend Favorite

In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist

By Ozaki S.   Kawamoto H.   Itoh Y.   Miyaji M.   Azuma T.   Ichikawa D.   Nambu H.   Iguchi T.   Iwasawa Y.   Ohta H.  

European Journal of Pharmacology, Vol. 402, Iss. 1, 2000-08 ,pp. : 45-53

Elsevier

Access to resources Recommend Favorite